AstraZeneca Launches Zegfrovy Lung Cancer Drug in US
AstraZeneca announced the U.S. launch of Zegfrovy (sunvozertinib), indicated for adults with locally advanced or metastatic non-small cell lung cancer carrying EGFR exon 20 insertions.
AstraZeneca announced the U.S. launch of Zegfrovy (sunvozertinib), indicated for adults with locally advanced or metastatic non-small cell lung cancer carrying EGFR exon 20 insertions.